Avalo Completes Enrollment for Phase 2 LOTUS Trial

Avalo Therapeutics ( (AVTX) ) has shared an update.

On December 2, 2025, Avalo Therapeutics announced the completion of enrollment for their Phase 2 LOTUS trial of AVTX-009 in treating hidradenitis suppurativa, with topline data expected in Q2 2026. The company highlights AVTX-009’s potential for best-in-class efficacy due to its high affinity and longer half-life compared to existing treatments, positioning it as a promising candidate in a market projected to exceed $10 billion by 2035.

The most recent analyst rating on (AVTX) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Avalo Therapeutics stock, see the AVTX Stock Forecast page.

Spark’s Take on AVTX Stock

According to Spark, TipRanks’ AI Analyst, AVTX is a Neutral.

The overall stock score for Avalo Therapeutics is primarily impacted by its poor financial performance, with significant challenges in revenue generation and profitability. While technical analysis shows some positive momentum, the negative valuation metrics further weigh down the score.

To see Spark’s full report on AVTX stock, click here.

More about Avalo Therapeutics

Avalo Therapeutics operates in the pharmaceutical and biotechnology industry, focusing on developing novel IL-1β therapies to address unmet medical needs in immune-mediated inflammatory diseases. Their lead compound, AVTX-009, is aimed at treating hidradenitis suppurativa, a chronic inflammatory skin condition.

Average Trading Volume: 395,195

Technical Sentiment Signal: Sell

Current Market Cap: $304.3M

Find detailed analytics on AVTX stock on TipRanks’ Stock Analysis page.